| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 28th February 2021 | Karen L Daniel | 183 | Grant/award etc. | $74.03 | $13,547.49 |
| 25th February 2021 | Sandra L Fenwick | 7,173 | Exercise of derivative | $0.00 | |
| 25th February 2021 | Karen L Daniel | 7,173 | Exercise of derivative | $0.00 | |
| 11th February 2021 | Karen L Daniel | 762 | Grant/award etc. | $0.00 | |
| 1st February 2021 | Glen Tullman | 164,931 | Exercise of derivative | $5.26 | $867,537.06 |
| 1st February 2021 | Glen Tullman | 164,931 | Open or private sale | $262.61 | $43,312,529.91 |
| 14th January 2021 | Glen Tullman | 164,931 | Exercise of derivative | $5.26 | $867,537.06 |
| 14th January 2021 | Glen Tullman | 164,931 | Open or private sale | $225.12 | $37,129,266.72 |
| 31st December 2020 | Karen L Daniel | 762 | Grant/award etc. | $65.70 | $50,063.40 |
| 8th December 2020 | Hemant Taneja | 4,900 | Open or private sale | $197.39 | $967,206.59 |
Livongo Health
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Livongo Health, Inc. develops and operates a consumer digital health platform. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008.
Ticker: LVGO
Sector: Technology Services
Industry: Packaged Software
SEC Central Index Key (CIK): 1639225
Employees: 615
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Increase Decrease In Due To Related Parties of $0 for the period Jan 2020 to Jun 2020 in the context of all up
Increase Decrease In Due To Related Parties of $2 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $686 M (0%)
Inventory, Net: $18 M (-39%)
Other Assets, Current: $0 (-100%)
Assets, Current: $951 M (95%)
Property, Plant and Equipment, Net: $16 M (0%)
Other Assets, Noncurrent: $569 Th (0%)
Assets: $1 B (87%)
Accounts Payable, Current: $6 M (-23%)
Accrued Liabilities, Current: $36 M (0%)
Liabilities, Current: $48 M (14%)
Other Liabilities, Noncurrent: $397 Th (-86%)
Liabilities: $471 M (785%)
Common Stock, Value, Issued: $100 Th (5%)
Retained Earnings (Accumulated Deficit): $171 M (0%)
Stockholders' Equity (Parent): $578 M (0%)
Liabilities and Equity: $1 B (87%)
Revenue: $92 M (-42%)
Cost of Revenue: $21 M (-45%)
Gross Margin: $70 M (-41%)
Research and Development: $16 M (-46%)
Sales and Marketing: $33 M (-45%)
General and Administrative Expenses: $22 M (-41%)
Operating Income/Loss: $262 Th (-96%)
Provision for income taxes: $72 Th (-22%)
